The Journal of Clinical Psychiatry published a study from the University of Oklahoma and Oklahoma State University, revealing that semaglutide may significantly reduce Alcohol Use Disorder (AUD) symptoms. Originally approved for diabetes and weight loss, semaglutide now shows promise in the field of addiction medicine.
Recent research indicates that semaglutide, a drug used for diabetes and weight loss, could effectively reduce symptoms of Alcohol Use Disorder. This finding, based on a study involving six patients, opens new avenues for addiction treatment and has led to further clinical trials.
The first published evidence from humans that semaglutide specifically reduces the symptoms of Alcohol Use Disorder (AUD) has been published in The Journal of Clinical Psychiatry and details a recent collaboration between clinicians and scientists at the University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences. The paper outlines the outcomes of six patients who received semaglutide during treatment for weight loss, demonstrating a significant and noteworthy decrease in their Alcohol Use Disorders Identification Test (AUDIT) scores.
Jesse Richards, director of Obesity Medicine and assistant professor of Medicine at OU-TU School of Community Medicine and lead author of the study. Credit: OU-Tulsa
The paper is titled “Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series.” This collaboration has the potential to impact the lives of individuals struggling with Alcohol Use Disorder.
Semaglutide has made headlines recently as an FDA-approved drug for the treatment of diabetes under the name Ozempic, and weight loss under the name Wegovy. Recently, attention has turned to the possibility that semaglutide may have broader applications, including its potential impact on addictive behaviors such as reducing drug craving and alcohol consumption. Pre-clinical research in rodents and monkeys has demonstrated that semaglutide is associated with marked decreases in drug and alcohol consumption, and many patients taking the drug for diabetes and weight loss report significant reductions in the urge to drink alcohol.
“This research marks a significant step forward in our understanding of the potential therapeutic applications of semaglutide in the field of addiction medicine,” said the lead author, Dr. Jesse Richards, director of Obesity Medicine and assistant professor of Medicine at OU-TU School of Community Medicine.
Key Takeaways from the Research:
Semaglutide Treatment and Alcohol Use Disorder: The study reveals a marked reduction in Alcohol Use Disorder Identification Test (AUDIT) scores in all six patients who received semaglutide treatment in the course of pharmacotherapy for weight loss. The results suggest a potential role for this medication in the management of Alcohol Use Disorder.
Implications for Future Research: The findings open new avenues for future research into the use of glucagon-like peptide-1 medications, such as semaglutide, in the treatment of addictive behaviors.
Collaborative Research Model: This collaboration between The University of Oklahoma School of Community Medicine and Oklahoma State University Center for Health Sciences is an example of the potential when clinicians and scientists collaborate to explore innovative solutions to complex healthcare challenges.
Dr. Kyle Simmons, the paper’s senior author and professor of Pharmacology & Physiology at OSU-Center for Health Sciences noted that this case series evidence paves the way for gold-standard placebo-controlled clinical trials such as the one he is currently conducting in Tulsa at the OSU Hardesty Center for Clinical Research and Neuroscience.
Called STAR (Semaglutide Therapy for Alcohol Reduction), the clinical trial is funded by the Hardesty Family Foundation and OSU-CHS. A sister study is also currently underway in Baltimore funded by the National Institute on Drug Abuse (NIDA).
“This is an example of what can happen when our two R-1 research institutions in Oklahoma collaborate,” said Simmons. “With the publication of this case series in the Journal of Clinical Psychiatry, the stage is set for future clinical trials, such as the STAR studies, which can definitively tell us whether semaglutide is safe and effective for treatment of alcohol use disorder.”
The researchers emphasized the need for further investigation through larger, controlled studies to validate and expand upon these initial findings. Until the results of future placebo-controlled clinical trials are available, the authors believe that healthcare providers should point patients toward established behavioral treatments and medications that have been validated by the FDA for alcohol use disorder.
Reference: “Significant Decrease in Alcohol Use Disorder Symptoms Secondary to Semaglutide Therapy for Weight Loss: A Case Series” by Jesse R. Richards, DO; Madisen Fae Dorand, MD; Kyleigh Royal; Lana Mnajjed; Maria Paszkowiak and W. Kyle Simmons, PhD, 27 November 2023, The Journal of Clinical Psychiatry.
DOI: 10.4088/jcp.23m15068
Source: SciTechDaily
